First Time Loading...

Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 3.8 USD -1.81% Market Closed
Updated: Apr 29, 2024

Fate Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fate Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Fate Therapeutics Inc
NASDAQ:FATE
Operating Income
-$190.5m
CAGR 3-Years
-14%
CAGR 5-Years
-23%
CAGR 10-Years
-27%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Fate Therapeutics Inc's Operating Income?
Operating Income
-190.5m USD

Based on the financial report for Dec 31, 2023, Fate Therapeutics Inc's Operating Income amounts to -190.5m USD.

What is Fate Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-27%

Over the last year, the Operating Income growth was 38%. The average annual Operating Income growth rates for Fate Therapeutics Inc have been -14% over the past three years , -23% over the past five years , and -27% over the past ten years .